Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3CMGM5
Thu, 07.11.2024
APONTIS PHARMA AG
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023: EUR 17.9 million)
Novartis collaboration (asthma products) contributes EUR 5.6 million to revenues
EBITDA rises to EUR 2.7 million (9M 2023: EUR [ … ]
Wed, 30.10.2024
APONTIS PHARMA AG
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
Joint reasoned statement by Management Board and Supervisory Board published
Offer price of EUR 10.00 per share represents an attractive premium of around 52.9% compared to the closing price on 15 October 2024 and a premium of 38.3% com [ … ]
Wed, 16.10.2024
APONTIS PHARMA AG
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA and Zentiva signed an investment agreement today
Growth strategy of APONTIS PHARMA to be continued together with Zentiva
APONTIS PHARMA to benefit from the European footprint, the existing research and [ … ]
Wed, 16.10.2024
APONTIS PHARMA AG
Publication of inside information pursuant to Article 17 of the Regulation (EU) No. 596/2014
APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
Monheim / Rhein, 16 October 2024. APONTIS PHARMA AG (“APONTIS PHARMA” or the “Company”, Ticker APPH / ISIN DE000A3CMGM5), Zentiva Pharma GmbH [ … ]
Fri, 16.08.2024
APONTIS PHARMA AG
Company Name:
APONTIS PHARMA AG
ISIN:
DE000A3CMGM5
Reason for the research:
Update
Recommendation:
BUY
from:
16.08.2024
Target price:
€17
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Christian Orquera
First Berlin Equity Research has published a research update on APONTIS PHARMA AG (ISIN: DE000A3CMGM [ … ]
Fri, 09.08.2024
APONTIS PHARMA AG
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
Revenue growth for Single Pill combinations in the first half of 2024 to EUR 17.9 million (H1 2023: EUR 12.1 million), also due to a competitor’s temporary inability to deliver in first quarter of 2024
New [ … ]
Thu, 27.06.2024
APONTIS PHARMA AG
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, expands its Executive Board with a view t [ … ]
Thu, 27.06.2024
APONTIS PHARMA AG
APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company
Monheim / Rhein, 27 June 2024. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pill combinations in the German market, expands its Executive Board with a view t [ … ]
Mon, 24.06.2024
APONTIS PHARMA AG
First Berlin Equity Research on 24/06/2024 initiated coverage on APONTIS
PHARMA AG (ISIN: DE000A3CMGM5/ Bloomberg: APPH GR). Analyst Christian
Orquera placed a BUY rating on the stock, with a EUR 17.00 price target.
Abstract:
Apontis Pharma AG (Apontis) is a leading specialty pharmaceutical company
focusing on the development and marketing of a [ … ]
Tue, 04.06.2024
APONTIS PHARMA AG
APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management
Mila Brückel appointed as Head of Supply Chain
Extensive expertise in managing global supply chain programs from positions at Merck Healthcare
Monheim / Rhein, 4 June 2024. APONTIS PHARMA AG (Ticker APPH [ … ]